Pepticom’s technology aims to ‘vastly reduce’ risk of failure in peptide drug candidates’ discovery and development, by utilizing artificial intelligence models.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
SignalPath announced the closing of its Series B funding round to support the expansion of its software platform, which facilitates clinical trials management.
Early dialogue with patients is ‘critical’ to design efficient clinical development programs for ATMPs and avoid ‘data gaps’, an executive from ARM says.
The research models and services provider has acquired a company that specializes in tissue collections, and hematology, and immunology cell isolations to help meet its ‘ever-increasing’ client needs.
Alkermes to work collaboratively with the Fred Hutchinson Cancer Research Center on the clinical development of a drug candidate as a combination treatment alongside Keytruda.
In the company’s latest partnership, TrialSpark has partnered with Limbix to design and implement a clinical trial for a digital therapeutic for adolescent depression.
dMed Biopharmaceutical recently raised approximately $50m in a Series B financing to further expand the CRO’s operations after launching three years ago.
UK government signs freight capacity contracts to mitigate the risk that trade disruption will stop medicines from reaching patients related to a potential no-deal Brexit.
Eversana boosts its logistics offering by opening its fourth storage and distribution center in the US, bringing its total footprint to one million-square-feet.
Novo Nordisk completes the construction of a wastewater treatment plant in Clayton, North Carolina, which will be donated to the city to aid biopharma growth.
While the prevalence of chronic diseases boosts the demand for self-administered treatments, ease of use is becoming more important in device manufacturing, says product specialist.
phaseUP is a new life sciences leadership firm that is looking to help pharma, biotech, and CROs build cohesive and collaborative teams – as the success or failure of a clinical development program depends on the people, says company founder.
Sponsors committed to standardizing data can benefit from ‘more than improved efficiency,’ says YPrime VP, as the company expands its eClinical portfolio to include data standards, clinical analytics and eCOA consulting services.
Yourway sets up a new EU-based location to provide storage and distribution services, including secondary packaging capabilities, as Brexit uncertainties abound.
Research has discovered that bacteria will open holes in their cell wall under certain conditions, potentially leading to a new drug target or greater potency of existing antibiotics.
US FDA approves Noven’s schizophrenia treatment administered through a once-daily transdermal delivery system, able to release the antipsychotic drug for 24 hours.
Organ-on-a-chip systems are poised to revolutionize drug development in many ways, say researchers advancing the technology, which could support gender-specific medicine, among other use cases.
An expansion to BIA Separations' Cornerstone set of processing services for viral vector development adds the use of kryptonase and CIMmultus chromatography device.
Trialbee and TriNetX are teaming up to accelerate research and develop new services with the goal of improving patient access to clinical trials as a care option.
Trinity’s acquisition of Bell Canyon aims to create an integrated data management offering that will enable all members of a development project to gain access to ‘a single version of truth.’
Aetion and McKesson today announced a strategic collaboration to advance the use of real world evidence in cancer research – offering joint solutions to support the FDA’s demonstration project and commercial customers.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.
Though the utilization of biosimilars in Europe is high, a report on the practices of eight countries suggests that more can be done to foster competition and remove barriers to entry.
The goal of the partnership between Life Image and Graticule is to improve clinical trial results and accelerate drug development, while reducing costs, say company executives.
US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.
A consortium between CPI and the University of Strathclyde aims to create a direct compression platform for continuous manufacturing of oral solid dosage drugs.
With global health care ‘at a tipping point,’ NSF International expands its services across the product lifecycle with the acquisition of a US-headquartered CRO, says VP.
The FDA has published the second in a series of guidance documents that aim to accelerate research and the use of patient input to inform clinical development programs, says Iqvia head.
Broad adoption of blockchain technology requires manufacturers to look at their investments in the supply chain, just as they look at R&D, AmerisourceBergen executive says.
With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
The clinical trials software company has raised $7.1m to connect its network of more than 5,000 clinical trial sites with sponsors and CROs via the ‘Florence eHub.’
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
TriNetX is a new technology partner working on the FDA’s Sentinel System, led by HPHCI, which has signed a contract worth up to $220m to develop a new Sentinel Innovation Center.
A fellowship program run by Worldwide Clinical Trials aims to equip scientists with the skills to meet industry demands for ‘informed, differentiated’ services.
